Combo of Merck's Keytruda, Pfizer's Inlyta Meets Primary Endpoints
October 18 2018 - 8:35AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Thursday said a Phase 3 study of its
cancer drug Keytruda in combination with Pfizer Inc.'s (PFE)
kidney-cancer drug Inlyta met both primary endpoints.
The Kenilworth, N.J., drug maker said the combination showed
statistically significant and clinically meaningful improvements in
overall survival and progression-free survival in the first-line
treatment of advanced or metastatic renal cell carcinoma, the most
common type of kidney cancer.
Merck said the study also met the key secondary endpoint of
objective response rate, with significant improvements for the
combination compared with sunitinib monotherapy.
Merck said fewer than 10% of patients diagnosed with advanced
renal cell carcinoma survive for five years. The companies plan to
submit the results to regulatory authorities world-wide.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2018 08:20 ET (12:20 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024
